Medicenna Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 20

Employees

  • Stock Symbol
  • MDNA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.12
  • (As of Friday Closing)

Medicenna Therapeutics General Information

Description

Medicenna Therapeutics Corp is the development and commercialization of IL-2, IL-4 and IL-13 Superkines and empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its platforms are Superkine, BISCUIT, TEMASK, Publications, and Scientific Publications.

Contact Information

Formerly Known As
A2 Acquisition
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2 Bloor Street West
  • Suite 903
  • Toronto, Ontario M4W 3E2
  • Canada
+1 (416)
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
TSE
Vertical(s)
Corporate Office
  • 2 Bloor Street West
  • Suite 903
  • Toronto, Ontario M4W 3E2
  • Canada
+1 (416)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medicenna Therapeutics Stock Performance

As of 20-Nov-2026, Medicenna Therapeutics’s stock price is $0.12. Its current market cap is $11.3M with 92.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.12 $0.15 $0.12 - $1.29 $11.3M 92.3M 74.7K -$0.16

Medicenna Therapeutics Financials Summary

As of 30-Jun-2026, Medicenna Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 21,339 30,805 32,722 79,316
Revenue 0 0 0 0
EBITDA (13,632) (13,649) (9,402) (19,757)
Net Income (13,430) (13,318) (8,471) (18,873)
Total Assets 5,804 6,069 19,832 14,161
Total Debt 73 85 117 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Medicenna Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Medicenna Therapeutics‘s full profile, request access.

Request a free trial

Medicenna Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Medicenna Therapeutics Corp is the development and commercialization of IL-2, IL-4 and IL-13 Superkines and empowered Su
Biotechnology
Toronto, Canada
20 As of 2026

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Medicenna Therapeutics Competitors (21)

One of Medicenna Therapeutics’s 21 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Cullinan Therapeutics Formerly VC-backed Cambridge, MA
Revive Therapeutics Corporation Toronto, Canada
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Achaogen Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 21 competitors. Get the full list »

Medicenna Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medicenna Therapeutics Acquisitions (1)

Medicenna Therapeutics’s most recent deal was a Merger/Acquisition with A2 Acquisition. The deal was made on 01-Mar-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
A2 Acquisition 01-Mar-2017 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Medicenna Therapeutics’s complete acquisitions history, request access »

Medicenna Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Medicenna Therapeutics’s complete esg history, request access »

Medicenna Therapeutics FAQs

  • When was Medicenna Therapeutics founded?

    Medicenna Therapeutics was founded in 2011.

  • Where is Medicenna Therapeutics headquartered?

    Medicenna Therapeutics is headquartered in Toronto, Canada.

  • What is the size of Medicenna Therapeutics?

    Medicenna Therapeutics has 20 total employees.

  • What industry is Medicenna Therapeutics in?

    Medicenna Therapeutics’s primary industry is Biotechnology.

  • Is Medicenna Therapeutics a private or public company?

    Medicenna Therapeutics is a Public company.

  • What is Medicenna Therapeutics’s stock symbol?

    The ticker symbol for Medicenna Therapeutics is MDNA.

  • What is the current stock price of Medicenna Therapeutics?

    As of 20-Nov-2026 the stock price of Medicenna Therapeutics is $0.12.

  • What is the current market cap of Medicenna Therapeutics?

    The current market capitalization of Medicenna Therapeutics is $11.3M.

  • Who are Medicenna Therapeutics’s competitors?

    Sarepta Therapeutics, Cullinan Therapeutics, Revive Therapeutics, Genetix Biotherapeutics, and Achaogen are some of the 21 competitors of Medicenna Therapeutics.

  • What is Medicenna Therapeutics’s annual earnings per share (EPS)?

    Medicenna Therapeutics’s EPS for 12 months was -$0.16.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process